From the Guidelines
Mavyret (glecaprevir/pibrentasvir) is typically prescribed as three tablets taken once daily with food for hepatitis C treatment, with a total daily dose of 300 mg of glecaprevir and 120 mg of pibrentasvir. The duration of treatment depends on the patient's hepatitis C genotype, liver status, and treatment history, but generally ranges from 8 to 16 weeks. For most treatment-naïve patients without cirrhosis, an 8-week course is sufficient, as recommended by the 2020 EASL guidelines 1. Patients with compensated cirrhosis or those who have been previously treated may require 12 or 16 weeks of therapy. Key factors influencing treatment duration include:
- Hepatitis C genotype
- Presence and severity of liver cirrhosis
- Prior treatment experience Mavyret works by targeting specific proteins in the hepatitis C virus, preventing viral replication. The once-daily dosing with food improves absorption and helps with patient adherence. It's essential to take Mavyret exactly as prescribed and complete the full course of treatment to maximize the chance of curing the hepatitis C infection, as supported by studies such as those published in the Journal of Hepatology 1 and Clinical and Molecular Hepatology 2, 3, 4, 5, 6, 7, 8.
From the FDA Drug Label
2.3 Recommended Dosage in Adults MAVYRET tablets are a fixed combination drug product containing glecaprevir 100 mg and pibrentasvir 40 mg in each tablet. The recommended oral dosage of MAVYRET in adults is 3 tablets taken at the same time once daily with food (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg)
The dose and frequency of Mavyret (glecaprevir and pibrentasvir) for Hepatitis C treatment in adults is:
- Dose: 3 tablets (glecaprevir 300 mg and pibrentasvir 120 mg)
- Frequency: once daily with food 9
From the Research
Dose and Frequency of Mavyret (Glecapadir and Pibrentasvir) for Hepatitis C Treatment
- The recommended dose of Mavyret is a fixed-dose combination tablet of glecaprevir and pibrentasvir, with oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily 10.
- The treatment duration may vary depending on the patient's condition, with options for 8-week or 12-week courses of treatment 11, 12, 13, 14.
Treatment Duration
- For patients without cirrhosis, an 8-week or 12-week course of treatment with glecaprevir-pibrentasvir may be effective, with high rates of sustained virologic response achieved in both treatment durations 11.
- For patients with compensated cirrhosis, a 12-week course of treatment with glecaprevir plus pibrentasvir has been shown to achieve high rates of sustained virological response, with 99% of patients achieving a sustained virological response at 12 weeks 13.
- In real-world practice, 8-week and 12-week treatment durations with glecaprevir/pibrentasvir have been found to be effective and well-tolerated in patients with cirrhosis, with rates of sustained virologic response ranging from 85.8% to 100% 12, 14.
Safety and Efficacy
- Glecaprevir/pibrentasvir has been found to be well-tolerated and effective in patients with chronic hepatitis C and cirrhosis, with low rates of adverse events and serious adverse events 12, 13, 14.
- The most common adverse events reported in clinical trials and real-world studies include fatigue and headache, with few patients discontinuing treatment due to adverse events 11, 12, 13, 14.